Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry-Reference-Cited by-同舟云学术

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Published:2004 Issue:23 Volume:18 Page:2839-2848
ISSN:0951-4198
Container-title:Rapid Communications in Mass Spectrometry
language:en
Short-container-title:Rapid Commun. Mass Spectrom.

Author:

Beumer Jan Hendrik,Rosing Hilde,Hillebrand Michel J. X.,Nan-Offeringa Lianda G. A. H.,Foley Karen,Yule S. Murray,Heck Albert J. R.,Schellens Jan H. M.,Beijnen Jos H.

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Analytical Chemistry

Reference7 articles.

1. Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer

2. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer

3. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

4. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses;Pharmacology Research & Perspectives;2015-03

2. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin;British Journal of Clinical Pharmacology;2008-10

3. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours;British Journal of Cancer;2008-04

4. CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity;Clinical Cancer Research;2007-05-15

5. A phase I and pharmacokinetic study of indisulam in combination with carboplatin;British Journal of Cancer;2007-02